The Global Sexual Health Market is anticipated to rise at a value CAGR of 4.9% over 2019-2028. According to a study published by Insure Insights on the Sexual Health Market, Sexual Health is essential for physical, mental, and social well-being, especially between couples so as to have a pleasurable and safe sexual experience, which is without sexual dysfunctions, and preventive measures to avoid sexually transmitted infections. Technological advances of new products to correct these dysfunctions are boosting the Global Sexual Health Market

Top Driver: The rise in the incidence and prevalence of sexual disorders is driving the market

Erectile Dysfunction, Absent or delayed ejaculation despite adequate sexual stimulation, early or premature ejaculation, Inability to relax the vaginal muscle are the various types of disorders that affects the sexual health. These are the major factors boosting the market and are very likely to affect the personal and social life of an individual. They have been a significant increase in the number of sexual dysfunction cases globally; for instance, WHO had reported that 43 percent of women and 31 percent of men report some degree of sexual dysfunction.  Thus these factors are driving the sexual health market.

Erectile Dysfunction drugs to Make Crucial Contribution to Growth of Global Sexual Health Market

Erectile Dysfunction drugs are expected to rule the market based on the type segment due to the rise in the incidences of Erectile Dysfunction; there are also various advances made in the drugs are expected to rule the market based on the type segment due to the rise in the incidences of the Erectile Dysfunction,

For instance CURE Pharmaceutical in March 2020,  had announced the allowance of a  Chinese Patent to treat erectile dysfunction, as per the patent in includes loading of high amounts of active drug on an oral thin film using its proprietary drug delivery systems, including its lead drug product, CUREfilm Blue, a soluble thin film for oral administration of sildenafil citrate. Based on the Gender Segment, Females Gender has driven the market due to the increased rate of dysfunctions in Females than Males. In terms of  Distribution Channel hospital pharmacies have dominated the market due to the increase in the hospital infrastructure and patience seeking physicians  help in the treatment

North America will continue to Rule the global Sexual Health Market

The rise in the sexual exploration and acceptance of Lesbian, Gay, Bisexual, Transgender, and Queer (LGBTQ+) community are enhancing the market growth of the region. Technological advances in the region, better healthcare infrastructure, rise in per capita income is boosting the growth of the market. The rising incidences and prevalence of sexual disorders and dysfunctions in the are the primary factors expanding the market growth, Government initiatives for better healthcare, R&D investments are further enhancing the market growth.

Strategic collaboration and acquisition, Joint Partnership are the major strategies of the competitors in the market

The competitors of the Sexual Health Market are being fragmented, the main competitors of the market are Teva Pharmaceutical Industries Ltd., Meda Pharmaceuticals, Inc., Eli Lilly & Company, Bayer AG, Vivus, Inc., Zydus Pharmaceuticals, Merck & Co., Pfizer Inc. Ltd., and Novartis International AG

Eli Lilly & Company: Eli Lilly & Company is a giant competitor of the Sexual Health Market and are also keen on providing various treatment to combat the dysfunction. For instance, in the year 2016, FDA had approved the drug Taltz to treat moderate-to-severe plaque psoriasis; however, on 2018 Eli Lilly and Company had reported that Taltz could be used in the treatment of severe genital psoriasis, and would help in combating the problems associated with sexual dysfunction.

Novartis International AG:  Novartis International AG is popular in the global Sexual Health Market. In January 2020, Novartis International AG had announced that it had completed the acquisition of The Medicines Company. The acquisition was made to strengthen its product portfolio in cholesterol-lowering therapy.

Scope of the Report

By Gender

• Male
• Female

By Drugs

• Erectile Dysfunction Drugs
• Gender Dysphoria Drugs
• Hypoactive Sexual Desire Disorder Drugs
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region

• North America
• Europe
• Asia Pacific
• LAMEA